These results indicate that BCc1 and cyclophosphamide treatments, regardless of administration route, effectively suppress mTOR expression in the tumor microenvironment, suggesting potential effects on mTOR-driven signaling pathways in tumor progression. This evidence concerns the gene MTOR and neoplasm.